



Date: - 14th November, 2022 To, Department of Corporate Services, BSE LIMITED, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 SCRIP CODE: 530843

The National Stock Exchange of India Ltd. Exchange Plaza, 5th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051 Fax No. – 6641 8125 / 26 SCRIP CODE: CUPID

Subject: - Investor Presentation

Dear Sir / Madam,

With reference to captioned subject attached herewith the Investor Presentation dated 14th November, 2022.

Kindly take the same on your records.

Thanking You.

Yours faithfully For Cupid Limited

Saurabh V. Karmase Company Secretary and Compliance Officer ECSIN: EA041701A000083921

CIN No.: L25193MH1993PLC070846

Factory & Registered Office:

A-68, M.I.D.C. (Malegaon), Sinnar, Nashik - 422113, Maharashtra, India Tel:+91 2551 230280 / 230772 / +91 7722009580 Email: info@cupidlimited.com, Website: www.cupidlimited.com



Investor Presentation







Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.



We at Cupid Limited are committed to play a promising role for the fight against HIV/AIDS & Prevention of Unintended Pregnancy.

Developing a safe and effective methodology against HIV is critical to our efforts to control the devastating pandemic of HIV/AIDS as

WE HELP THE WORLD PLAY SAFE...





CUPID AT A GLANCE




WHO ARE WE TODAY?



India's Leading manufacturer of male condom, female condoms and water based lubricant jelly	20+ years of Industry experience	1 st company in the world to get WHO/UNFPA Prequalification for both Male & Female Condom	Debt Free balance Sheet
Annual Capacity: Male (480mn) & Female (52mn) condoms Lubricant Jelly (210mn sachets)	Presence in 90+ countries	Employs 100+ people with average experience of 10 years	Low Equity Base
Helping Global Organizations in prevention of HIV/STI's and Unintended Pregnancy	Over 85% revenues from Direct exports	Robust diversification plans and strong order book	Long Term agreements with WHO/UNFPA

CUPID'S JOURNEY








FINANCIAL PERFORMANCE




QUARTERLY HIGHLIGHTS (Q2FY23)









Q2FY23 Performance

- Total Operating income was ₹452.5 million (mn) for Q2FY23 as compared to ₹327.9 mn in the corresponding period of the previous year, an increase of 38.0%.
- EBITDA stood at ₹120.0 mn as compared to ₹55.2 mn during the corresponding period of previous year, an increase of 117.5%.
- EBITDA Margin at 26.5% for Q2FY23 as against 16.8% in Q2FY22.
- Net profit stood at ₹85.8 mn for Q2FY23 as compared to ₹46.5 mn in the corresponding period of the previous year, an increase of 84.6%.
- Basic EPS stood at ₹6.43 as against ₹3.48 in Q2FY22.



SALES BREAKUP

- Exports in Q2FY23 was 97% (88% in Q2FY22) of the total revenue while domestic sale was 3% (12% in Q2FY22).
- The product mix in Q2FY23 was Male condoms (MC) 67% (78% in Q2FY22), Female condoms (FC) with 17% (13% in Q2FY22), Others (Lubricant Jelly) 15% (8% in Q2FY22) and IVD sales 1% (1% in Q2FY22).

BUSINESS HIGHLIGHTS/OUTLOOK

- ISO 13485 certificate obtained for IVD products during the quarter. This will permit exports of IVD products.
- Recorded the highest ever percentage of export sales at over 97% during the quarter.
- Input costs exhibited stable price trend.
- Strong order book worth Rs. 169 crores as on October, 2022.

BUSINESS OUTLOOK

- We expect improvement in overall performance in FY23 based on the execution of the orders in hand and expected order wins in the near term.
- With comfortable margins and stabilizing raw material prices, the future focus will be on increasing growth and profitability

INCOME STATEMENT



Particulars (In ₹mn)	Q2FY22	Q3FY22	Q4FY22	Q1FY23	Q2FY23
Income from Operations	327.9	362.2	313.6	308.2	452.5
Total Income	340.8	369.8	324.3	314.9	462.1
Cost of Material Consumed	164.0	148.9	188.3	161.9	201.7
Change in Inventory	-11.2	46.0	-34.0	-14.5	-27.3
Employee Benefit Expenses	30.5	26.3	24.8	28.6	29.6
Other Expenses	89.4	105.2	69.1	74.4	128.5
EBITDA (Inc other Income)	68.0	43.5	76.1	64.6	129.6
EBITDA Margin (Ex other Income)	16.8%	9.9%	24.3%	18.8%	26.5%
Depreciation	6.1	6.2	8.1	6.5	7.1
EBIT	61.9	37.3	68.0	58.1	122.5
EBIT Margin	18.9%	10.3%	21.7%	18.8%	27.1%
Finance Cost	0.4	0.4	0.4	0.8	0.6
PBT	61.5	37.0	67.7	57.3	121.8
Total Taxes	15.0	12.0	25.8	10.9	36.0
Net Profit For The Period	46.5	23.6	41.9	46.3	85.8
Net Profit Margin	14.2%	6.5%	13.4%	15.0%	19.0%
EPS (Basic)	3.48	1.77	3.14	3.47	6.43



ABOUT US



CUPID FACTORY (AREA >100000 SQ. FEET)





TECHNICAL CAPABILITY





- World Class manufacturing facility with conformity with global standards and best quality practices
- Housed with Richter-Hi Tech German dipping technology and online electronic testing. So, every unit produced is electronically tested before dispatch
- Established operating procedures and defined processes to ensure zero defect quality
- Installed capacity to produce over 480 million male condoms
 - and close to 52 million female condoms

IN-HOUSE LABORATORY



WELL EQUIPPED IN-HOUSE LABORATORY WITH TRAINED AND EXPERIENCED PERSONNEL TO CONDUCT BELOW TESTING

- In-coming Raw & Packaging material testing
- In-process product testing
- Finished product testing:
 - \circ Dimensions
 - o Burst Volume & Burst Pressure
 - o Visual Defects
 - o Freedom from holes
 - Package seal integrity
 - o Lubricant quantity
 - Packaging and Marking




CERTIFICATIONS & ACCREDITATIONS





PRODUCTS AND BUSINESS





MALE CONDOMS



Male Condoms are available in different varieties like Plain, Dotted, Ribbed, Multi-textured, Extra Large & Ultra-Thin. They are also available in different flavours & colours with 49mm, 53mm & 56mm width. Primary packs are available in rectangular, square & circular format. All condoms are 100% electronically tested.

> INSTALLED CAPACITY OF 480 MILLION PIECES PER YEAR



A few major brands of Cupid Limited

CUPID DIG DOM HI-LIFE BULL FANTASY D'sire STUD Green Love

FEMALE CONDOMS









- Cupid Female Condom commercial production started in 2010.
- Cupid Female Condoms are available with or without flavor and color.
- Installed capacity of 52 million pieces per year.



- Water based Lubricant Jelly is used with condoms to enhance pleasure. Cupid Limited started manufacturing lubricant jelly in 2015.
- Water based Lubricants are available in different pack sizes starting from 4.5ml sachets, Laminated Tubes and bottles.
- Installed capacity of 210 million sachets per year.
- Currently Lubricants are being exported to more than 30 countries world over. Also started getting regular orders from WHO/UNFPA for sachets and tubes.



UPCOMING PRODUCTS:- IN VITRO DIAGNOSTIC DEVICE (IVD)





Syphilis Ab Test

- Chromatographic immunoassay
- Detection of Specific TP antibodies
- Specimen: Serum /Plasma
- Result interpretation time: 20 min
- Sensitivity: 100 %
- Specificity: 100 %



HIV 1 & 2 Ab Test

- Chromatographic immunoassay
- Detection of HIV 1 & 2 antibodies
- Specimen: Serum/plasma
- Result interpretation time: 20 min
- Sensitivity: 100 %
- Specificity: 100 %



Viral Transport Medium

- Intended use: for the collection and transport of clinical specimens containing viruses
- Easy to handle and use
- No other accessories required



Typhoid IgG/IgM Test

- Chromatographic immunoassay
- Detection of S. typhi specific antibodies
- Specimen: Serum/Plasma
- Result interpretation time: 10-15 min

UPCOMING PRODUCTS:- IN VITRO DIAGNOSTIC DEVICE (IVD)





Malaria Pf-PAN Ag Test

- Chromatographic immunoassay
- Detection of Pf-HRP II and PANpLDH specific antigens
- Specimen: Whole blood
- Result interpretation time: 15-20 min
- Sensitivity: 100 %
- Specificity: 100 %



Hepatitis B (HbsAG) Ag Test

- Chromatographic immunoassay
- Detection of Hepatitis B antigens
- Specimen: Serum/Plasma
- Result interpretation time: 20 min
- Sensitivity: 99.5 %
- Specificity: 99.0 %

Malaria Pf-Pv Ag Test

- Chromatographic immunoassay
- Detection of Pf-HRP II and Pv-pLDH specific antigens
- Specimen: Whole blood
- Result interpretation time: 15-20 min
- Sensitivity: 100 %
- Specificity: 100 %



Hepatitis C (HCV) Ab Test

- Chromatographic immunoassay
- Detection of HCV antibodies
- Specimen: Serum/Plasma
- Result interpretation time: 20 min
- Sensitivity: 99.5 %
- Specificity: 99.0 %







Pregnancy HCG Detection Test

- Chromatographic immunoassay
- Detection of HCG levels
- Result interpretation time: 5 min
- Specimen: Urine
- Sensitivity: 98.7 %
- Specificity: 99.6 %



Dengue IgG-IgM Ab Test

- Chromatographic immunoassay
- Detects Dengue Antibodies
- Specimen: Serum/Plasma
- Result interpretation time: 15-20 min
- Sensitivity: 100%
- Specificity: 100%



LH Ovulation Rapid Test

- Chromatographic immunoassay
- Detection of Luteinizing hormone
- Specimen: Urine

- Result interpretation time: 10 min
- Sensitivity: 99.8 %

Strong In-House Manufacturing Capabilities





COMPOUNDING

SECTION

DIPPING SECTION



TESTING SECTION



SEALING SECTION

Strong In-House Manufacturing Capabilities







FEMALE CONDOM SECTION



LUBRICANT JELLY SECTION



QUALITY TESTING LAB SECTION

PACKING SECTION


24

CUPID'S GEOGRAPHICAL PRESENCE




South Africa	Kenya	Rwanda	Zimbabwe	Netherlands	Switzerland
Haiti	Trinidad	Brazil	Indonesia	Denmark	Burma
Ghana	Nigeria	Gabon	Benin	UAE	Ivory Coast
Uganda	Nepal	Srilanka	Congo	USA	Syria
Jamaica	Belarus	New Zealand	Australia	Ecuador	Cameroon
Albania	Azerbaijan	Bhutan	Burundi	Comoros	Cuba
DRC	Guinea Bissau	Honduras	Tajikistan	Gautemala	Morocco
Ukraine	Central African Republic	Tanzania	Uzbekistan	Brazil	Jordan
Mali	Nicaragua	Pakistan	Portugal	Sudan	Zambia
Dominican Republic	Gambia	Guyana	Guinea	Kuwait	Liberia
Mozambique	Afghanistan	Malawi	Russia	Sierra Leone	Belize





Turnover in Million. USD






3 Years Sales Data

Sale Quantity(Male condom) in Million Pieces

Sale Quantity(Female Condom) in Million Pieces



CUPID IN SOCIAL MEDIA






Stock Profile

Listing	BSE(1995) / NSE (2016)
Issued Shares (mn)	13.338
Share Price(INR)^	~249
Market Cap^(INR mn)	~3,326
52-week Range(INR)	353.70-192.05

Corporate Information

BSE / NSE Scrip Code	530843/CUPID
ISIN	INE509F01011
CIN	L25193MH1993PLC070846
BLOOMBERG	CUPD-IN

^ as per BSE closing price of 14th November 2022



Contact Details

Saurabh Karmase (Company Secretary & Compliance Officer)

T: + 91 2551 230280 / 230178 E: cs@cupidlimited.com

Binay Sarda

Ernst & Young LLP T: + 91 22 6192 0000 E: binay.sarda@in.ey.com



Thank You

